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channel CFTR. Whereas established therapies for the treatment of cystic fibrosis target CFTR to re-
pair its function, alternative therapeutic strategies aim for the restoration of chloride transport by the
activation of other chloride transport proteins such as TMEM16A or SLC26A9 or by the application
of synthetic anionophores. TMEM16A is an anion-selective channel that is activated by the binding of
Ca2+ from the cytoplasm. Pharmacological efforts aim for the increase of its open probability at resting
Ca2+ concentrations. SLC26 is an uncoupled chloride transporter, which shuttles chloride across the
membrane by an alternate-access mechanism. Its activation requires its mobilization from intracellular
stores. Finally, anionophores are small synthetic molecules that bind chloride to form lipid-soluble com-
plexes, which shuttle the anion across the membrane. All three approaches are currently pursued and
have provided promising initial results.
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Cystic fibrosis is a hereditary disease that originates from mutations in the epithelial chloride 
channel CFTR. Whereas established therapies for the treatment of cystic fibrosis target CFTR to 
repair its function, alternative therapeutic strategies aim for the restoration of chloride transport by 
the activation of other chloride transport proteins such as TMEM16A or SLC26A9 or by the 
application of synthetic anionophores. TMEM16A is an anion-selective channel that is activated 
by the binding of Ca2+ from the cytoplasm. Pharmacological efforts aim for the increase of its open 
probability at resting Ca2+ concentrations. SLC26 is an uncoupled chloride transporter, which 
shuttles chloride across the membrane by an alternate-access mechanism. Its activation requires 
its mobilization from intracellular stores. Finally, anionophores are small synthetic molecules that 
bind chloride to form lipid-soluble complexes, which shuttle the anion across the membrane. All 




The apical side of airway epithelia is covered by a thin layer of mucus, which has a protecting 
function and thus needs to be constantly renewed by a process called muco-ciliary clearance. This 
process requires the proper hydration of the epithelial surface at the air-water interface, which is 
ensured by the continuous transport of water across the epithelium following the secretion of salt 
[1]. In cystic fibrosis (CF), a hereditary disease affecting 0.03% of the Caucasian population, this 
process is impaired due to the loss of function of the chloride channel cystic fibrosis 
transmembrane regulator (CFTR) [2, 3], which in airway epithelia is predominantly expressed in 
ciliated cells. The impairment of proper hydration is associated with the hyper-concentration of 
mucus, which results in impaired clearance facilitating the emergence of infections. Different 
mutations of CFTR leading to cystic fibrosis either decrease its open probability or compromise 
its folding and trafficking to the plasma membrane [4]. Established strategies directed towards the 
treatment of this debilitating disease involve the restoration of the function of CFTR by 
pharmacological agents that either increase its open probability or improve its targeting to the 
membrane [5, 6]. However, the lack of protein production as a consequence of the premature 
termination of translation, which is a characteristic of class I mutations, and the variable 
therapeutic responses among patients containing different mutations of CFTR to its 
pharmacological rescue underscore the need for complementary approaches to tackle this 
condition. Recent alternative strategies thus aim at the stimulation of alternative chloride transport 
pathways in airway epithelia to compensate for the loss of function of CFTR. Such strategies either 
attempt for the activation of existing chloride transport proteins or the introduction of artificial 
chloride transport pathways by application of membrane-permeable carriers [5, 7]. Alternative 
chloride transport proteins in native respiratory epithelia encompass, amongst others, the calcium-
activated chloride channel TMEM16A and the chloride transporter SLC26A9 whereas small 
synthetic carriers, which bind chloride and shuttle it across cellular membranes, would be applied 
to the tissue from the outside. These potential alternative targets for the treatment of cystic fibrosis 
are described in the following chapters. This review is based on two presentations at the 16th ECFS 
Basic Science Conference, Dubrovnik, Croatia, 27 to 30 March, 2019. 
 
2. The calcium-activated chloride channel TMEM16A 
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Whereas a calcium-activated chloride conductance was observed in airway epithelia more than 
thirty years ago [8], the underlining molecular identity of the channel remained elusive until the 
discovery of TMEM16A as calcium-activated chloride channel about ten years ago [9-11]. In these 
epithelia, TMEM16A is predominantly expressed on the apical side of mucus-producing goblet 
cells [12]. The protein is activated by the elevation of the cytosolic calcium concentration as a 
consequence of cellular signaling processes. TMEM16A is part of the TMEM16/anoctamin family 
of membrane proteins that encompasses 10 paralogs in human, which either form channels for ions 
or lipids [13, 14]. Whereas TMEM16A and B are working as bona fide anion channels, their 
paralogs function as lipid scramblases [15]. Latter facilitate the movement of lipids between both 
leaflets of the bilayer thereby dissipating the lipid asymmetry and exposing the negatively charged 
phosphatidyl-serine to the outside, which in turn activates signaling cascades leading to blood 
coagulation, exocytosis and myoblast fusion [14]. Both functional branches of the family share a 
common molecular architecture and a conserved mechanism of calcium activation that was 
initially defined by the crystal structure of the lipid scramblase nhTMEM16 [16, 17] and later by 
the structures of murine TMEM16A determined by cryo-electron microscopy (cryo-EM) [18-20]. 
All TMEM16 proteins are homo-dimers of subunits that contain an N-terminal domain followed 
by a transmembrane unit consisting of ten membrane-spanning α-helices (Fig. 1A). The catalytic 
regions contained within each subunit are located at the opposite ends of the dimer and function 
as independent entities with respect to activation and transport [21, 22]. In TMEM16 scramblases, 
this region termed the ‘subunit cavity’ exposes a hydrophilic membrane-spanning furrow that 
provides a suitable pathway for lipid headgroups across the membrane [16]. In contrast, in the ion 
channel TMEM16A, the rearrangement of α-helices constituting the subunit cavity in nhTMEM16 
have closed the access to the bilayer and instead form a protein-enclosed pore that is for most parts 
shielded from the membrane [18]. In the conducting state, the hour-glass shaped pore contains 
wide hydrophilic vestibules on both sides of the membrane narrowing to an amphiphilic neck 
region which conducts anions that have likely shed large parts of their hydration shell [19] (Fig. 
1B). In TMEM16A, this pore does not contain specific anion binding sites and its strong anion 
over cation selectivity is instead a consequence of the positive electrostatic environment [18]. 
Activation of the protein proceeds by the binding of two Ca2+ ions to a site contained within the 
transmembrane domain of each subunit that is accessible form the intracellular side and located in 
the vicinity of the ion conduction pore [19] (Fig. 1C). This site consists of five negatively charged 
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residues that are strongly conserved within the family [16]. The location of the Ca2+-binding site 
within the transmembrane electric field explains the observed voltage-dependence of activation 
with increased potency of Ca2+ at positive voltages [16]. The binding of Ca2+ to the closed channel 
promotes ion conduction by two distinct mechanisms: It causes a conformational change of one 
helix (α6), which contributes to the ion binding site and which has retracted from the pore region 
in the absence of Ca2+ [19] (Fig. 1C). The rearrangement of α6 transduces a conformational change 
to open a gate in the narrow pore region and it reverts the repulsive electrostatics on the 
intracellular pore entry conferred by the negatively charged binding site residues into a positive 
electrostatic environment that facilitates anion conduction [23]. Thus, in TMEM16A, Ca2+ directly 
contributes to ion conduction by a mechanism that is highly unusual for ligand-dependent ion 
channels. Any therapeutic strategy that is directed towards channel activation by an increase of the 
open probability thus also has to compensate the negative electrostatics of the vacant binding site 
that would hamper anion efflux, which would be best accomplished by a concomitant increase of 
the Ca2+-potency towards nanomolar concentrations found in a resting epithelium. Noteworthy, 
besides activation of TMEM16A also a potential opposing strategy aiming at its inhibition has 
been discussed [24]. Latter proposal was motivated by the presumed role of TMEM16A in the 
contraction of endothelial sooth muscles and its association with mucus secretion where the 
proposed inhibition might prevent hypersecretion under inflammatory conditions. 
 
3. The chloride transport protein Slc26a9 
SLC26A9 is a chloride transport protein that is expressed in ciliated cells of airway epithelia. Its 
activity is enhanced under inflammatory conditions where it was shown to substantially contribute 
to epithelial chloride transport and thus to prevent mucus obstruction [25]. Whereas, upon 
heterologous overexpression, its localization was found to be predominantly intracellular, 
presumably as consequence of the interaction with WNK kinases [26], the protein was proposed 
to undergo functional interactions with CFTR, which potentially regulates its transport function 
and targeting to the plasma membrane [27-29]. SLC26A9 is a member of the large SLC26 family, 
which constitutes multifunctional anion transport proteins that are found in all kingdoms of life 
[30]. Whereas most of the ten functional paralogues in human were shown to be involved in the 
transport of chloride, bicarbonate, oxalate, iodide and sulfate, SLC26A5 (or Prestin) appears to 
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have lost its transport activity and instead works as chloride-dependent motor protein in cochlear 
outer hair cells [31]. Unlike the majority of mammalian family members, which function as 
coupled anion exchangers, SLC26A9 mediates uncoupled chloride transport and, although 
frequently referred to as ion channel, works as bidirectional uniporter that mediates rapid chloride 
transport by an alternate-access mechanism [26, 32]. Although transporting different anions by a 
lyotropic permeability sequence that favors larger ions with lower hydration energy, the 
biologically important anions bicarbonate and sulfate are not transported by SLC26A9 [32]. The 
general structural features of the SLC26 family were initially revealed from the crystal structure 
of the prokaryotic homologue SLC26Dg, working as proton-coupled fumarate symporter [33]. 
This structure has defined the overall organization of the family consisting of a transmembrane 
domain (TMD) followed by a cytoplasmic STAS domain, but it did not reveal the oligomeric 
organization of SLC26 transporters, which form dimers as later confirmed by a spectroscopic study 
of the protein [34]. The detailed oligomeric structure of SLC26A9 was uncovered by cryo-EM 
[32], which defined the common architecture of mammalian members of the SLC26 family (Fig. 
1D). The unusual dimeric arrangement exhibits minimal interactions between the TMDs and 
dimerization is instead mediated by mutual contacts between the domain-swapped STAS domain, 
their interaction with the TMD of the neighboring subunit and the extended N-terminus of the 
protein (Fig. 1D). This organization differs from dimeric transporters of the SLC4 and SLC23 
families, which show a similar organization of the TMD but which bury an extended interaction 
interface within the membrane [35]. Despite their interactions via the STAS domain, the two 
TMDs likely work as independent entities. They are organized by a 7+7 inverted repeat topology 
with two structurally related halves that are oriented with opposite orientations relative to the 
membrane [35]. Each TMD segregates into two interacting structural sub-domains consisting of 
helices of both halves, which were termed core and gate modules (Fig. 1E) The core module 
contains an anion-binding site located on the surface of the protein apposed to the gate module in 
the center of the protein (Fig 1F). This site can be reached via aqueous vestibules which, depending 
on the conformation of the transporter, provide access to either one or the other side of the 
membrane and which confer a positive electrostatic environment attracting anions on the path to 
the binding site [32]. In this site, the bound ion is located in a narrow pocket and interacts with 
polar and hydrophobic residues, which likely accounts for the observed selectivity sequence 
favoring larger anions (Fig. 1G). The movements of the protein are illustrated in the comparison 
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of two structures of SLC26A9 determined in detergent and in lipid nanodiscs, which show different 
conformations [32]. During transport, the gate modules and interacting STAS domains function as 
rigid scaffolds, whereas the mobile core module of each TMD carrying the ion binding site moves 
as rigid unit to change the exposure of the site to either side of the membrane, thereby crossing the 
transmembrane electric field in a process that was previously defined as ‘elevator mechanism’ 
[36]. Although transport appears to be constitutive and not regulated by activating ligands, the 
proposed functional interaction with CFTR and the signals that regulate the trafficking of 
SLC26A9 are still poorly understood [26, 27]. The exploitation of this protein as pharmacological 
target for the treatment of cystic fibrosis would thus have to improve the plasma membrane 
expression in absence of functional CFTR.   
 
4. Ionophores as alternative chloride transport systems  
Another potential alternative to compensate for the reduced CFTR anion transport activity are 
small molecules capable of facilitating the permeation of chloride and bicarbonate across epithelial 
membranes. These molecules, termed anionophores (for anion selective ionophores), are a recent 
addition to the research in cystic fibrosis [5]. Anionophores are able to coordinate anions through 
non-covalent interactions such as hydrogen bonds. In this way, a supramolecular complex is 
formed that provides a lipophilic shell for the anion thus allowing its diffusion across the 
membrane [37]. In stark contrast to cation-selective ionophores or pore-forming molecules, only 
few natural products have been identified to act as anionophores. Therefore, numerous synthetic 
molecules are being developed, including macrocycles such as calix[4]pyrroles and small 
molecules bearing convergent hydrogen bond donor groups such as amides, (thio)ureas, 
sulfonamides or squaramides [37]. Prodigiosin is the lead example of naturally occurring 
anionophores, naming a family of compounds with intriguing pharmacological properties [38]. 
Related molecules are marine secondary metabolites termed Tambjamines. Based on these natural 
compounds, synthetic analogues with anionophoric properties have been synthesized [39]. These 
molecules have been shown to promote anion transport into living cells in a concentration-
dependent manner. Measurements of iodide influx in FTR cells expressing a halide-sensitive YFP 
protein allowed quantification of the anion transport activity by these compounds in relationship 
to the activity of CFTR. The transport efficiency was found to be pH dependent with a maximum 
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at slightly acidic pH values [40]. Under these conditions, the measured quenching rate is 
comparable to that observed for CFTR. The activity was also found to be sustained over time and 
no decay of quenching rate was observed for periods up to one hour. Since bicarbonate is equally 
important for epithelial physiology, an ideal anionophore would also be able to correct the 
compromised transport of this anion. Using a pH-based assay, bicarbonate transport promoted by 
synthetic anionophores was demonstrated in Fischer rat thyroid (FRT) cells [41]. Interestingly, the 
activity of synthetic anionophores has been shown to be additive to the pharmacological rescue of 
CFTR activity [41]. Thus, in FRT cells expressing G551D‐CFTR, rescue of the mutated‐CFTR 
activity by ivacaftor was additive to that driven by anionophores. Similar results were observed 
when the F508del‐CFTR activity was rescued by the corrector lumacaftor.   
The use of cholic acid as scaffold provided a different series of highly active anionophores [42]. 
This steroidal framework allows the placing of up to three (thio)-urea groups in an axial, 
convergent disposition, thereby creating a polar pocket suitable to bind spherical anions.  These 
anionophores, termed cholapods, have been shown to promote anion transport in FRT cells and 
their activity was further confirmed by electrophysiological studies in epithelia [43]. Using the 
Ussing chamber technique anionophore mediated Cl− currents in the apical membrane of FRT 
epithelia were recorded. 
An encouraging result involving the use amphotericin B was recently reported [44]. Amphotericin 
B is a channel-forming molecule capable of facilitating unselective ion permeation in membranes. 
In this study, Amphotericin B restored airway surface liquid pH, viscosity and antibacterial activity 
in cultured airway epithelia derived from genetically diverse humans with CF. Using a clinically 
approved formulation of this compound (termed AmBisome) the restoration of airway surface 
liquid pH in vivo was demonstrated in a porcine model of CF. The success of this approach offers 
further evidence for the potential of small molecules acting as CFTR surrogates for correcting 
defective anion transport. Although the toxicity resulting from an exogenous transport mechanism 
and the selective targeting of small molecule anionophores to the apical membranes remain 
important issues that require further studies, current data indicate that the use of anionophores 





In this review, we have described three transport systems that facilitate the flow of chloride ions 
across the apical membrane of airway epithelia, which could compensate for the loss of activity of 
the CFTR channel. These three systems operate by different mechanisms with TMEM16A 
functioning as Ca2+-gated ion channel where the ligand also plays an important role in shaping the 
conductance properties, SCL26A9 as uncoupled bidirectional transporter, which potentially 
interacts with CFTR and anionophores acting as mobile carriers, which bind chloride to permit its 
diffusion across the membrane (Figure 2C). The restoration of chloride transport could either 
proceed by the activation of the two native transport proteins or the introduction of ionophores to 
the apical side of the epithelia. In this respect, the exploitation of either transport system presents 
a promising alternative therapeutic strategy for the treatment of cystic fibrosis. Whereas two 
approaches, namely the activation of the ion channel TMEM16A by potentiators [45] and the use 
of ionophores [44] are currently pursued and have provided promising initial results, investigations 
on the activation of SLC26A9 are still at an early stage [28]. 
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Fig. 1. Anion transport proteins in airway epithelia. A. Ribbon representation of the dimeric Ca2+-
activated chloride channel TMEM16A viewed from within the membrane. Membrane boundaries 
are indicated. Region containing the ion conduction pore in one of the subunits is highlighted as 
grey box. B. Closeup of the anion permeation pore.  The molecular surface of the pore is shown 
as grey mesh. C. Conformational changes upon Ca2+-binding to a site contained within the 
transmembrane domain. Top, Ca2+-bound open conformation, bottom, Ca2+-free closed 
conformation, with movements of α6 indicated by arrow. A-C, bound Ca2+ ions are shown as green 
spheres, the α-helix involved in gating (α6) is labeled. D. Ribbon representation of the dimeric 
chloride transporter SLC26A9 viewed from within the membrane. Transmembrane domain 
(TMD) and cytoplasmic STAS domain (STAS) are labeled and membrane boundaries indicated. 
E. Single TMD viewed from the extracellular side with core and gate modules labeled and shown 
in unique colors. F, Core module viewed from within the membrane. G. Closeup of the anion 
binding pocket with side-chains of surrounding residues displayed as sticks. Molecular surface of 




Fig. 2. A. schematic view of the complexation of Cl- by an anionophore (left) and its transport 
across the membrane (right). B. Chemical structure of an anionophore derived from the natural 
compound Prodigiosin. C. Schematic summary of transport mechanisms. Left, the Ca2+-activated 
ion channel TMEM16A; Center, the transporter SLC26A9; Right, a synthetic anion-selective 
carrier. A-C, Cl- and Ca2+ are depicted as green and red spheres respectively. 
